UBS Group AG lowered its stake in shares of Enhabit, Inc. (NYSE:EHAB – Free Report) by 37.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,960,568 shares of the company’s stock after selling 1,172,421 shares during the quarter. UBS Group AG owned approximately 3.87% of Enhabit worth $18,076,000 as of its most recent SEC filing.
A number of other large investors have also added to or reduced their stakes in EHAB. 8 Knots Management LLC raised its position in Enhabit by 9.5% in the third quarter. 8 Knots Management LLC now owns 4,218,846 shares of the company’s stock worth $33,793,000 after acquiring an additional 365,779 shares during the period. Arrowstreet Capital Limited Partnership grew its position in shares of Enhabit by 96.5% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 640,074 shares of the company’s stock valued at $6,170,000 after acquiring an additional 314,401 shares during the period. Marshall Wace LLP grew its position in shares of Enhabit by 59.2% during the 3rd quarter. Marshall Wace LLP now owns 792,981 shares of the company’s stock valued at $6,352,000 after acquiring an additional 294,999 shares during the period. Bank of America Corp DE increased its stake in shares of Enhabit by 73.3% during the 3rd quarter. Bank of America Corp DE now owns 687,934 shares of the company’s stock worth $5,510,000 after purchasing an additional 290,978 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Enhabit by 8.2% during the 3rd quarter. Vanguard Group Inc. now owns 3,393,069 shares of the company’s stock worth $27,178,000 after purchasing an additional 256,559 shares during the last quarter.
Enhabit Stock Performance
Shares of EHAB stock opened at $13.80 on Wednesday. The firm’s 50 day moving average is $13.76 and its 200 day moving average is $11.21. The stock has a market capitalization of $706.72 million, a P/E ratio of -153.28 and a beta of 1.26. Enhabit, Inc. has a 12 month low of $6.47 and a 12 month high of $14.22. The company has a current ratio of 1.56, a quick ratio of 1.56 and a debt-to-equity ratio of 0.70.
Wall Street Analyst Weigh In
Several equities analysts recently commented on EHAB shares. Truist Financial set a $13.80 price objective on Enhabit in a research note on Monday, February 23rd. TD Cowen reissued a “hold” rating and issued a $13.80 target price (up from $12.00) on shares of Enhabit in a research report on Friday, March 6th. Deutsche Bank Aktiengesellschaft upgraded Enhabit to a “buy” rating in a research note on Tuesday, January 13th. Jefferies Financial Group cut Enhabit from a “buy” rating to a “hold” rating and upped their price target for the company from $12.50 to $13.80 in a research report on Monday, February 23rd. Finally, Oppenheimer downgraded Enhabit from an “outperform” rating to a “market perform” rating in a research note on Monday, February 23rd. Two investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $13.57.
Read Our Latest Stock Report on EHAB
Insider Buying and Selling at Enhabit
In related news, EVP Julie Diane Jolley sold 2,793 shares of the business’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $13.63, for a total transaction of $38,068.59. Following the sale, the executive vice president directly owned 139,923 shares in the company, valued at approximately $1,907,150.49. The trade was a 1.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 3.40% of the company’s stock.
Enhabit Profile
Enhabit, Inc (NYSE: EHAB) is a national provider of home-based healthcare services, offering a continuum of care designed to support patients in the comfort of their own homes. The company’s core mission is to deliver personalized clinical and non-clinical services that help individuals recover from illness or injury, manage chronic conditions, and, when necessary, receive compassionate end-of-life care. Enhabit’s business model centers on combining skilled clinical care with patient-centric service coordination to optimize outcomes and enhance the overall care experience.
The company’s service portfolio includes skilled nursing, physical, occupational and speech therapies, personal care assistance, palliative care and hospice services.
Featured Articles
- Five stocks we like better than Enhabit
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
Receive News & Ratings for Enhabit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enhabit and related companies with MarketBeat.com's FREE daily email newsletter.
